Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
Autor: | Teresa Santantonio, Bettina E. Hansen, Tania M. Welzel, Harry L.A. Janssen, Robert J. de Knegt, Maria Buti, Pauline Arends, Ivana Carey, Y.H. Oo, Roeland Zoutendijk, Katja Deterding, Massimo Fasano, Thomas Berg, David Mutimer, Ashley Brown, Milan J. Sonneveld, Jörg Petersen, Florian van Bömmel, Pierre Pradat, Fabien Zoulim, Heiner Wedemeyer, Jurriën G.P. Reijnders |
---|---|
Přispěvatelé: | Gastroenterology & Hepatology |
Rok vydání: | 2015 |
Předmět: |
Adult
Male Hepatitis B virus medicine.medical_specialty Carcinoma Hepatocellular Guanine Population medicine.disease_cause Antiviral Agents Risk Assessment Gastroenterology White People Hepatitis B Chronic SDG 3 - Good Health and Well-being Risk Factors Internal medicine medicine Humans Cumulative incidence education neoplasms Retrospective Studies education.field_of_study business.industry Incidence Incidence (epidemiology) Liver Neoplasms Entecavir Middle Aged Hepatitis B medicine.disease United Kingdom digestive system diseases Surgery Hepatocellular carcinoma DNA Viral Female business Risk assessment Follow-Up Studies medicine.drug |
Zdroj: | Gut, 64(8), 1289-1295. BMJ Publishing Group |
ISSN: | 0017-5749 |
Popis: | Background Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population. Methods We studied all HBV monoinfected patients treated with ETV from 11 European referral centres within the VIRGIL Network. Results A total of 744 patients were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 patients (22%) had cirrhosis. During a median follow-up of 167 (IQR 82-212) weeks, 14 patients developed HCC of whom nine (64%) had cirrhosis at baseline. The 5-year cumulative incidence rate of HCC was 2.1% for non-cirrhotic and 10.9% for cirrhotic patients (p |
Databáze: | OpenAIRE |
Externí odkaz: |